PM
ALXN

Parametrica Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Parametrica Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6,263
Closed -$610K – 340
2018
Q4 		$610K Buy
+6,263
New +$740K 0.74% 11
2016
Q4 		– Sell
-1,890
Closed -$232K – 283
2016
Q3 		$232K Buy
+1,890
New +$243K 0.64% 81

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Parametrica Management's ALXN Position: Q1 2019 in Review

Parametrica Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 6,263 shares — an estimated $610K sold.

Parametrica Management first reported a position in ALXN in Q3 2016 and held it in 2 quarters. The position peaked at $610K in Q4 2018. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

  • Parametrica Management reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Parametrica Management sold 6,263 Alexion Pharmaceuticals shares in Q1 2019, an estimated $610K.
  • Parametrica Management first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Parametrica Management's Alexion Pharmaceuticals position peaked at $610K in Q4 2018.
  • 611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Parametrica Management's 13F filing for Q1 2019, filed 7 May 2019.